Gavi and Multivalent Meningococcal Conjugate Vaccine;

1. w ww.gavi.org
Gavi and Multivalent Meningococcal
Conjugate Vaccine
Lee Hampton, MD, MSc

2. Conflicts of Interest: None
2

3. Gavi and Meningococcal Vaccines
• Meningococcal A Conjugate Vaccine (i.e., MenAfrivac) rollout
began in 2010 with Gavi support, with 26 countries in the African
meningitis belt eligible for Gavi funding support
• Routine immunization
• Preventive campaigns targeting individuals 1-29 years of age
• No meningococcal A cases identified in belt since 2018
• In 2018, non-A outbreaks prompted Gavi Board to authorize
multivalent meningococcal conjugate vaccine, contingent on
• Availabilityof a licensed product
• Outcomes of regulatoryand technical review processes
(including WHO PQ and SAGE recommendations)
• Meeting of specific vaccinecost targets
3

4. 4

5. 5

6. 6

7. Approximate
Expenditure /
Death Averted
1900
3700
120
200
500
2000
600
1200
1800
7
Gavi 2021-2025 Investment Case - https://www.gavi.org/sites/default/files/publications/2021-2025-Gavi-Investment-Opportunity.pdf
Risk-based
MMCV: $6,300 to
$13,400 per
death averted